Worth reading
55In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-142
¥ millions (operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials on financial results2026年5月期 第2四半期6 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥10,675 million
Operating profit¥-142 million
Ordinary income¥-131 million
Net income¥-191 million net profit attributable to owners of the parent
Operating profit margin
rate_pct-1.3
Full-year earnings forecast
Net Sales
¥23,600 million
EBITDA
¥1,015 million
Operating profit
¥327 million
Ordinary income
¥240 million
Profit attributable to owners of the parent
¥100 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Consolidated
Net Sales45.2%
EBITDA16.2%
Operating profit▲43.7%
Ordinary income▲54.9%
Profit attributable to owners of the parent▲191.4%
By segment
Medical Care Sales business
Net Sales44.3%
EBITDA17.1%
Healthcare Sales business
Net Sales40.3%
EBITDA21.0%
Healthcare Marketing business
Net Sales48.9%
EBITDA32.7%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
売上高およびEBITDAの通期計画に対する進捗は限定的New initiatives
- SOKUYAKUベネフィットの導入拡大
- Vポイントとの連携開始
- 病院・クリニック公式ホームページとAPI連携する予約機能の無料提供開始
- 予約不要の『今すぐ診療』機能のリリース
- ダイヤル・サービスの医療相談窓口との連携
- 静岡ジェードとのパートナーシップ契約
- 日本セルプセンター会員施設へのSOKUYAKU・検査キット提供
- Rosiの販売代理店契約
- 生漢煎シリーズ『大柴胡湯錠SP』の新発売
- 完全ドリンク酵水素328選もぎたて生スムージーの新発売
- LILAYオーバルシャンプーブラシの新発売
- FAVEURクリスマスコフレの数量限定発売
Key KPIsA metric the company considers important as a management benchmark.
- QAU (quarterly active users)103 10,000 people
- ARR (annual recurring revenue)32 Hundred millions of yen
Segment results
Medical Care Sales business
Net Sales
¥2,588 million
EBITDA
¥130 million
Operating profit
¥108 million
Healthcare Sales business
Net Sales
¥2,759 million
EBITDA
¥101 million
Operating profit
¥-121 million
Healthcare Marketing business
Net Sales
¥5,327 million
EBITDA
¥143 million
Operating profit
¥82 million
Medium-term management plan targets
Deepening the SOKUYAKU healthcare ecosystem in Japan and creating the same ecosystem in Asian marketsMarket Size / Share
日本のオンライン診療市場は2022年から2028年にかけて拡大見込み。世界のTelemedicine Marketは2020年15.2十億ドル、2028年60.1十億ドル（予測）| Item | Details |
|---|---|
| Document type | Presentation materials on financial results |
| Fiscal Period Covered | 2026年5月期 第2四半期 |
| Net Sales | ¥10,675 million |
| Operating profit | ¥-142 million |
| Ordinary income | ¥-131 million |
| Net income | ¥-191 million (net profit attributable to owners of the parent) |
| Operating profit margin | rate_pct -1.3 / yoy_change_points Not disclosed |
| Full-year earnings forecast | Net Sales ¥23,600 million / EBITDA ¥1,015 million / Operating profit ¥327 million / Ordinary income ¥240 million / Profit attributable to owners of the parent ¥100 million |
| Progress against full-year forecast | Consolidated Net Sales 45.2% / EBITDA 16.2% / Operating profit ▲43.7% / Ordinary income ▲54.9% / Profit attributable to owners of the parent ▲191.4% / By segment Medical Care Sales business Net Sales 44.3% / EBITDA 17.1% / Healthcare Sales business Net Sales 40.3% / EBITDA 21.0% / Healthcare Marketing business Net Sales 48.9% / EBITDA 32.7% |
| Self-assessment against the plan | 売上高およびEBITDAの通期計画に対する進捗は限定的 |
| Segment results | Medical Care Sales business Net Sales ¥2,588 million / EBITDA ¥130 million / Operating profit ¥108 million / Healthcare Sales business Net Sales ¥2,759 million / EBITDA ¥101 million / Operating profit ¥-121 million / Healthcare Marketing business Net Sales ¥5,327 million / EBITDA ¥143 million / Operating profit ¥82 million |
| Key KPIs | Indicator name QAU (quarterly active users) / Value 103 10,000 people / Year on year against the same period last year Not disclosed, Indicator name ARR (annual recurring revenue) / Value 32 Hundred millions of yen / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | Deepening the SOKUYAKU healthcare ecosystem in Japan and creating the same ecosystem in Asian markets |
| Market Size / Share | 日本のオンライン診療市場は2022年から2028年にかけて拡大見込み。世界のTelemedicine Marketは2020年15.2十億ドル、2028年60.1十億ドル（予測） |
| New initiatives | SOKUYAKUベネフィットの導入拡大, Vポイントとの連携開始, 病院・クリニック公式ホームページとAPI連携する予約機能の無料提供開始, 予約不要の『今すぐ診療』機能のリリース, ダイヤル・サービスの医療相談窓口との連携, 静岡ジェードとのパートナーシップ契約, 日本セルプセンター会員施設へのSOKUYAKU・検査キット提供, Rosiの販売代理店契約, 生漢煎シリーズ『大柴胡湯錠SP』の新発売, 完全ドリンク酵水素328選もぎたて生スムージーの新発売, LILAYオーバルシャンプーブラシの新発売, FAVEURクリスマスコフレの数量限定発売 |
Items this document does not state (16)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.下期以降の売上高に寄与する新規定期顧客の獲得を目的に広告投資を強化したため。会社は、ROI重視の顧客獲得戦略を継続したことも理由として挙げている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.